426 related articles for article (PubMed ID: 30086150)
21. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
[TBL] [Abstract][Full Text] [Related]
22. Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.
Christodoulou M; Aspray TJ; Piec I; Fraser WD; Schoenmakers I;
Age Ageing; 2024 May; 53(5):. PubMed ID: 38770543
[TBL] [Abstract][Full Text] [Related]
23. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
24. Intact FGF23 and α-Klotho during acute inflammation/sepsis in CKD patients.
Dounousi E; Torino C; Pizzini P; Cutrupi S; Panuccio V; D'Arrigo G; Abd ElHafeez S; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2016 Mar; 46(3):234-41. PubMed ID: 26728476
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor 23 and Klotho serum levels in healthy children.
Gkentzi D; Efthymiadou A; Kritikou D; Chrysis D
Bone; 2014 Sep; 66():8-14. PubMed ID: 24880094
[TBL] [Abstract][Full Text] [Related]
26. Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients.
Tan SJ; Satake S; Smith ER; Toussaint ND; Hewitson TD; Holt SG
Eur J Clin Nutr; 2017 Feb; 71(2):180-184. PubMed ID: 27848940
[TBL] [Abstract][Full Text] [Related]
27. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
[TBL] [Abstract][Full Text] [Related]
28. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
[TBL] [Abstract][Full Text] [Related]
29. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
[TBL] [Abstract][Full Text] [Related]
31. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
[TBL] [Abstract][Full Text] [Related]
32. Serum Phosphate Levels Modify the Impact of FGF23 Levels on Hemoglobin in Chronic Kidney Disease.
Navarro-González JF; Mora-Fernández C; Diaz-Tocados JM; Bozic M; Bermúdez-López M; Martín M; Valdivielso JM
Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432528
[TBL] [Abstract][Full Text] [Related]
33. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
[TBL] [Abstract][Full Text] [Related]
34. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
[TBL] [Abstract][Full Text] [Related]
35. The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children.
Efthymiadou A; Kritikou D; Mantagos S; Chrysis D
Eur J Endocrinol; 2016 Apr; 174(4):473-9. PubMed ID: 26764419
[TBL] [Abstract][Full Text] [Related]
36. Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial.
Mercadal L; Tezenas du Montcel S; Chonchol MB; Debure A; Depreneuf H; Servais A; Bassilios N; Assogba U; Allouache M; Prié D
Am J Nephrol; 2018; 48(5):349-356. PubMed ID: 30408788
[TBL] [Abstract][Full Text] [Related]
37. High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis.
Fang YW; Wang JT; Lin TY; Lee CJ; Jang TN; Tsai MH; Liou HH
Front Med (Lausanne); 2023; 10():1098871. PubMed ID: 37081846
[TBL] [Abstract][Full Text] [Related]
38. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
Block GA; Rosenbaum DP; Yan A; Greasley PJ; Chertow GM; Wolf M
Nephrol Dial Transplant; 2019 Feb; 34(2):339-346. PubMed ID: 29617976
[TBL] [Abstract][Full Text] [Related]
39. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.
Sharma S; Katz R; Ginsberg C; Bullen A; Vallon V; Thomson S; Moe OW; Hoofnagle AN; de Leeuw PW; Kroon AA; Houben AJHM; Ix JH
J Bone Miner Res; 2022 Jun; 37(6):1170-1178. PubMed ID: 35373859
[TBL] [Abstract][Full Text] [Related]
40. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
